Tenax Common Stock Total Equity from 2010 to 2024

TENX Stock  USD 6.01  0.07  1.18%   
Tenax Therapeutics Common Stock Total Equity yearly trend continues to be fairly stable with very little volatility. Common Stock Total Equity will likely drop to 1,079 in 2024. Common Stock Total Equity is the total value of common stock equity held by shareholders, representing their ownership interest in the company. View All Fundamentals
 
Common Stock Total Equity  
First Reported
1996-09-30
Previous Quarter
1.5 K
Current Value
2.5 K
Quarterly Volatility
525.4 K
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Tenax Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tenax Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.2 K, Other Operating Expenses of 8.4 M or Research Development of 3.6 M, as well as many indicators such as Price To Sales Ratio of 141.3 K, Dividend Yield of 3.31 or PTB Ratio of 0.71. Tenax financial statements analysis is a perfect complement when working with Tenax Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Tenax Therapeutics Correlation against competitors.
For more information on how to buy Tenax Stock please use our How to Invest in Tenax Therapeutics guide.

Latest Tenax Therapeutics' Common Stock Total Equity Growth Pattern

Below is the plot of the Common Stock Total Equity of Tenax Therapeutics over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. Tenax Therapeutics' Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tenax Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Common Stock Total Equity10 Years Trend
Slightly volatile
   Common Stock Total Equity   
       Timeline  

Tenax Common Stock Total Equity Regression Statistics

Arithmetic Mean30,131
Geometric Mean1,907
Coefficient Of Variation365.58
Mean Deviation53,089
Median1,262
Standard Deviation110,153
Sample Variance12.1B
Range428.2K
R-Value(0.44)
Mean Square Error10.6B
R-Squared0.19
Significance0.10
Slope(10,798)
Total Sum of Squares169.9B

Tenax Common Stock Total Equity History

2024 1079.01
2023 1135.8
2020 1262.0
2019 674.0
2018 379.0
2017 141.0

About Tenax Therapeutics Financial Statements

Tenax Therapeutics investors use historical fundamental indicators, such as Tenax Therapeutics' Common Stock Total Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Tenax Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Common Stock Total Equity1.1 K1.1 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Tenax Stock Analysis

When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.